Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmedical mutual - ohio Litfulo prior auth Coverage …
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Litfulo (ritlecitinib) — prior authorization for alopecia areata

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization guidance for pharmacy benefit coverage of Litfulo (ritlecitinib) for treatment of alopecia areata in patients aged 12 years and older; describes approval criteria, durations, and conditions not recommended for approval.

    Policy Summary
    Payermedical mutual - ohio
    PolicyLitfulo (ritlecitinib) — prior authorization for alopecia areata
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain prior authorization and ensure initial prescriptions are by or in consultation with a dermatologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥12minimum age
    ≥6 moepisode duration
    ≥50%scalp hair loss
    6 moinitial approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 yr
    continuation approval

    Coverage Criteria for Litfulo (ritlecitinib)

    Initial Therapy and Continuation Therapy

    Approve when ALL of the following criteria are met for Initial Therapy (A) or Continuation (B):

    Initial Therapy (A)

    • Age: Patient is >= 12 years of age>= 12 years
    • Episode duration: Patient has a current episode of alopecia areata lasting >= 6 months>= 6 months
    • Extent: Patient has >= 50% scalp hair loss>= 50%
    • Prior therapies: Patient has tried at least one of: (a) conventional systemic therapy OR (b) high- or super-high potency topical corticosteroid

      Examples of conventional systemic therapies include corticosteroids, methotrexate, and cyclosporine; exception if patient has already tried Leqselvi or Olumiant

    • Exclusion of other causes: Patient does not have hair loss due to androgenetic alopecia, chemotherapy-induced hair loss, or other causes of hair loss other than alopecia areata
    • Prescriber: Medication is prescribed by or in consultation with a dermatologist (specialist)

    Currently Receiving Litfulo (B)

    • Age: Patient is >= 12 years of age>= 12 years
    • Established therapy: Patient has been established on Litfulo for at least 6 months>= 6 months on therapy

      Patients with <6 months or restarting are reviewed under Initial Therapy

    • Clinical response: Patient experienced a beneficial clinical response defined as improvement from baseline in extent and density of scalp hair lossimprovement from baseline
    • Ongoing need:

    Use caution and do not approve Litfulo when it would be used concurrently with other systemic biologic therapies or targeted synthetic oral small-molecule drugs for inflammatory conditions. Do not administer Litfulo in combination with another biologic or a targeted synthetic oral small molecule drug because combination therapy is generally not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy.

    The policy excludes hair loss from causes other than alopecia areata. Coverage is not appropriate for hair loss due to androgenetic alopecia (male or female pattern hair loss), chemotherapy‑induced hair loss, trichotillomania, telogen effluvium, or systemic lupus erythematosus. These etiologies do not meet the Recommended Authorization Criteria.

    Coverage is not recommended for concurrent administration of Litfulo with other immunomodulatory or immunosuppressive agents. Specifically, do not combine Litfulo with another JAK inhibitor (including topical JAK inhibitors), with other biologics, or with biologic immunomodulators. Co‑administration with other potent immunosuppressants (for example, cyclosporine or azathioprine) is also discouraged because of added immunosuppression and absence of data demonstrating safety or additive benefit.

    Litfulo should only be considered for the indications and patient circumstances explicitly listed in the Recommended Authorization Criteria. Coverage is not recommended for uses, combination regimens, or clinical situations that are not specified in those criteria; the policy will be updated as new published data become available.

    Clinical Thresholds and Coding-related Criteria

    inv-06: Minimum scalp hair loss required for coverage.
    Minimum scalp hair loss>= 50% scalp hair loss
    ContextRequired for Initial Therapy approval (item iii).
    Applies toPatients being considered for Litfulo (ritlecitinib) initiation for alopecia areata
    inv-07: Minimum duration of current alopecia areata episode required for initial approval.
    Minimum episode duration>= 6 months current episode
    ContextRequired for Initial Therapy approval (item ii).
    Applies to

    Initial Therapy — Authorization Rules

    Initial Therapy

    Approve when ALL of the following criteria are met for Initial Therapy (A) or Continuation (B):

    Initial Therapy (A)

    • Age: Patient is >= 12 years of age>= 12 years
    • Episode duration: Patient has a current episode of alopecia areata lasting >= 6 months>= 6 months
    • Extent: Patient has >= 50% scalp hair loss>= 50%

    Continuation Therapy — Renewal Rules

    Continuation Therapy

    Criteria for patients currently receiving Litfulo

    Continuation criteria: Approve for 1 year if: patient >=12 years; on Litfulo >=6 months; experienced beneficial clinical response (improvement from baseline in extent and density of scalp hair); prescriber states patient continues to require systemic therapy1 year

    Patients with <6 months or restarting are reviewed under initial therapy

    Prescriber and Documentation Requirements

    Prior Authorization

    Prior authorization and specialist prescriber required

    Prior authorization is recommended for pharmacy benefit coverage of Litfulo; initial prescriptions must be by or in consultation with a physician who specializes in the condition being treated.

    Step Therapy

    Fail‑first / conservative therapy required before initial approval

    Initial approval requires trial of at least one conventional systemic therapy OR a high- or super-high‑potency topical corticosteroid; exception allowed if the patient has already tried Leqselvi (deuruxolitinib) or Olumiant (baricitinib).

    • Conventional systemic therapy examples include corticosteroids, methotrexate, and cyclosporine.
    • If patient has tried Leqselvi or Olumiant, the conventional‑therapy requirement can be waived.

    Background on Litfulo (ritlecitinib)

    Litfulo (ritlecitinib) is a kinase inhibitor in the JAK/TEC pathway indicated for treatment of severe alopecia areata in patients aged ≥ 12 years. Initial prescribing and monitoring should involve specialist expertise (for example, a dermatologist) because evaluation, diagnosis, monitoring for adverse events, and assessment of long‑term efficacy require dermatologic oversight. The policy cautions against combination use with other JAK inhibitors, biologics, biologic immunomodulators, or potent immunosuppressants due to safety concerns and limited evidence for additive efficacy.

    Definitions and Examples

    inv-13: Alopecia totalis / universalis — subtypes of alopecia areata noted as examples.
    Examples listedAlopecia universalis and alopecia totalis are noted as subtypes of alopecia areata.
    ContextPolicy explicitly identifies these as subtypes in the Recommended Authorization Criteria note.
    ImplicationThese subtypes are encompassed by the alopecia areata indication for Litfulo coverage.
    inv-14: Androgenetic alopecia and other excluded causes of hair loss.
    Excluded causesAndrogenetic alopecia (male and female pattern) is excluded and does not meet criteria for coverage.
    Other excluded causesOther excluded causes listed include chemotherapy-induced hair loss, trichotillomania, telogen effluvium, and systemic lupus erythematosus.

    Prescribing Site of Care Recommendation

    Note

    Specialist involvement for initial prescribing

    Initial prescribing should be by or in consultation with a physician who specializes in the condition being treated (e.g., dermatologist).

    Policy Summary
    Payermedical mutual - ohio
    PolicyLitfulo (ritlecitinib) — prior authorization for alopecia areata
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain prior authorization and ensure initial prescriptions are by or in consultation with a dermatologist.
    SourceLink
    On This Page
    Coverage Criteria for Litfulo (ritlecitinib)Clinical Thresholds and Coding-related CriteriaInitial Therapy — Authorization RulesContinuation Therapy — Renewal RulesPrescriber and Documentation RequirementsBackground on Litfulo (ritlecitinib)Definitions and ExamplesPrescribing Site of Care Recommendation
    Prescriber indicates patient continues to require systemic therapy for alopecia areata

    International consensus: discontinue systemic treatment once complete regrowth maintained for 6 months or when regrowth manageable topically

    Patients being considered for Litfulo initiation for alopecia areata
  1. Prior therapies: Patient has tried at least one of: (a) conventional systemic therapy OR (b) high- or super-high potency topical corticosteroid

    Examples of conventional systemic therapies include corticosteroids, methotrexate, and cyclosporine; exception if patient has already tried Leqselvi or Olumiant

  2. Exclusion of other causes: Patient does not have hair loss due to androgenetic alopecia, chemotherapy-induced hair loss, trichotillomania, telogen effluvium, systemic lupus erythematosus, or other non–alopecia areata causes

    Concurrent use with other biologics, topical JAK inhibitors, biologic immunomodulators, or other potent immunosuppressants is not recommended

  3. Prescriber: Medication is prescribed by or in consultation with a dermatologist (specialist)

    Prior authorization recommended; initial prescriptions must be by or in consultation with a specialist

  4. Currently Receiving Litfulo (B)

    • Age: Patient is >= 12 years of age>= 12 years
    • Established therapy: Patient has been established on Litfulo for at least 6 months>= 6 months on therapy

      Patients with <6 months or restarting are reviewed under Initial Therapy

    • Clinical response: Patient experienced a beneficial clinical response defined as improvement from baseline in extent and density of scalp hair lossimprovement from baseline
    • Ongoing need: Prescriber indicates patient continues to require systemic therapy for alopecia areata

      International consensus: discontinue systemic treatment once complete regrowth is maintained for 6 months or when regrowth is manageable with topical therapy

    Provider documentation and authorization risks: The Company may request patient records, test results, and/or provider credentials to support medical necessity; lack of adequate documentation may lead to denial of reimbursement if care is not medically necessary, investigational, outside member benefits, or billing is inappropriate/excessive

    Ensure records demonstrate prior therapy trials, extent/duration of hair loss, specialist involvement, and clinical response as applicable

    Fail-first / conservative therapy requirement: For initial approval, patient must have tried at least one conventional systemic therapy OR a high- or super-high potency topical corticosteroid (exception if patient has already tried Leqselvi or Olumiant)

    Document type, dose, and duration of prior therapies in medical record

    Step Therapy

    Fail‑first/conservative therapy required before initial approval

    Require evidence of a prior trial of at least one conservative therapy before initial approval. The patient must have tried either (a) a conventional systemic therapy (examples: corticosteroids, methotrexate, cyclosporine) or (b) a high- or super-high potency topical corticosteroid; an exception to this trial requirement is allowed if the patient has already tried Leqselvi (deuruxolitinib) or Olumiant (baricitinib).

    • Trial of ≥1 conventional systemic therapy OR a high- or super-high potency topical corticosteroid is required prior to initial approval.
    • Examples of conventional systemic therapies: corticosteroids, methotrexate, cyclosporine.
    • Exception: no conservative-therapy trial required if patient has already tried Leqselvi (deuruxolitinib) or Olumiant (baricitinib).
    Documentation Required

    Provide records, test results, and provider credentials on request

    The Company may request additional documentation to support medical necessity; requested materials may include patient records, test results, and/or credentials of the provider ordering or performing the service.

    Denial Risk

    Denial risk if documentation or medical necessity not met

    The Company may deny reimbursement when the drug or services are not medically necessary, are investigational or experimental, are not within the member's benefit scope, or when a pattern of billing or other practice is inappropriate or excessive.

    ContextRequirement v specifies patient must not have hair loss due to these excluded causes for Initial Therapy approval.